Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to compare the bioavailability of Par Lisinopril 40 mg Tablets and IPR Pharmaceuticals, Inc. Zestril (R).


Clinical Trial Description

To compare the bioavailability of Par Lisinopril 40 mg Tablets and IPR Pharmaceuticals, Inc. Zestril (R), 40 mg - Effect of Food Study ;


Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label


Related Conditions & MeSH terms

  • To Determine Bioequivalence Under Fed Conditions

NCT number NCT01380431
Study type Interventional
Source Par Pharmaceutical, Inc.
Contact
Status Completed
Phase Phase 1
Start date August 1999
Completion date October 1999

See also
  Status Clinical Trial Phase
Completed NCT00652600 - Bioavailability Study of Propranolol Under Fed Conditions Phase 1
Completed NCT01380496 - Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fed Conditions Phase 1
Completed NCT00652821 - Bioavailability Study of Tramadol/APAP Tablets Under Fed Conditions Phase 1
Completed NCT00652873 - Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fed Conditions Phase 1
Completed NCT00652704 - Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting and Fed Conditions Phase 1
Completed NCT00652730 - Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting and Fed Conditions Phase 1
Completed NCT05337969 - The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Assessed. N/A
Completed NCT05329857 - The Study Intends to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Evaluated. N/A
Completed NCT00653003 - Bioavailability Study of Leflunomide Tablets Under Fed Conditions Phase 1